Hive The Couch

	Main Index Search Register Login Who's Online FAQ Links
	Main Index Search Register Login Who's Online FAQ Links

	2 Online, 0 Active		You are not logged in

This is a historical archiveThe forum is read-only. Private information has been removed. It is not possible to login.

	The Couch

All 4 posts Subject: New Weight Loss - Quit Smoking Drug Please login to post Thread expires Down

ChemoSabe
(Hive Addict)
11-10-04 12:38
No 540813
User Picture       New Weight Loss - Quit Smoking Drug

http://seattletimes.nwsource.com/html/nationworld/2002086823_dietpill10.html

Wednesday, November 10, 2004 - Page updated at 12:00 A.M.

Tests bolster weight-loss drug

By Marilynn Marchione

NEW ORLEANS — The biggest test yet of an experimental drug that offers the fairy-tale promise of helping people lose weight and quit smoking found that it helped people not only drop pounds but also keep them off for two years — longer than any other diet drug has been able to achieve. Cholesterol and other health measures improved, too.

The impressive results from a study of more than 3,000 obese people were presented at a medical conference yesterday, capping months of anticipation about the new drug, Acomplia, made by the French pharmaceutical firm Sanofi-Aventis.

Doctors called the research exciting and the company, which funded the study, thinks the drug could have blockbuster potential similar to cholesterol-lowering statin drugs.

In a study of 3,040 obese people in the United States and Canada, those given the higher of two doses of the drug lost more than 5 percent of their initial body weight, and a third of them lost more than 10 percent.

"They achieved and maintained a weight loss of 19 pounds as compared to 5.1 pounds in the placebo group," said Dr. F-Xavier Pi-Sunyer of Columbia University in New York, who led the research and presented the results at the American Heart Association conference.

Those who quit taking the pill in the second year of the study regained most of what they had lost, suggesting that people might have to take the drug indefinitely to maintain a lower weight.

"We consider this to be a chronic problem. You don't cure obesity, you just improve it," Pi-Sunyer said.

About two-thirds of American adults are overweight or obese, raising their risk of everything from cancer and cardiovascular disease to sore joints and snoring. About a fourth of American adults smoke, which brings many of the same woes.

It has been devilishly difficult to develop effective treatments for either problem. Diet drugs in particular have a checkered history, most notably the withdrawal from the market in 1997 of the popular "fen-phen" drug combination after users developed heart-valve problems. Drugs now on the market are either designed for short-term use or have distasteful side effects like bowel problems that make many shy away from them.

Acomplia is the first diet drug aimed at blocking the "pleasure center" of the brain and interfering with the cycle of craving and satisfaction that drives many compulsive behaviors and addictions. This same circuitry is activated when people smoke marijuana. Sanofi plans to seek federal approval for it next year.

"Weight regulation is really kind of an addictive behavior," said Dr. Robert Eckel, an expert on metabolism from the University of Colorado Health Sciences Center, who had no role in the study.

The study involved people who either were severely obese or were moderately obese and also had another heart-related health problem such as low "good" cholesterol, high blood pressure or high blood sugar.

They were given nutrition advice and urged to cut 600 calories a day from their diet, and were randomly assigned to get either a 5- or 20-milligram dose of Acomplia or a placebo. Neither they nor their doctors knew who had received which.

After one year, those on the higher dose had lost an average of 19 pounds — the same result found in two smaller studies of the drug reported earlier this year.

The new study went on to test whether staying on the drug kept people from regaining weight. Those who took Acomplia during the first year were redivided to either continue on it or get a placebo for the second year.

At the end of the two years, 62.5 percent of people on the higher dose had lost 5 percent of their body weight, compared with 36.7 percent on the low dose and 33.2 percent on the placebo.

Waistlines shrank 3.1 inches with the higher dose, 1.9 inches with the lower one and 1.5 inches for those on the placebo.

HDL or "good" cholesterol rose 24.5 percent on the higher dose, 15.6 percent on the lower one and 13.8 percent on the placebo. Triglycerides also fell according to dose.

Most people in the study lost weight over six to seven months, then plateaued. Researchers said that's probably the limit of what the drug can do and that further weight loss should not be expected.

Some people on the drug had nausea, but it usually was short-lived.

"There was no evidence this drug over two years had something we had to worry about in the way of safety," Pi-Sunyer said.

Dr. Sidney Smith Jr., a University of North Carolina cardiologist who had no role in the study, said: "The results are very encouraging. The safety profile looks good. It seems like people tolerate the medication."

"It would be nice if this could be used as a jump-start" to get people to permanently change lifestyle habits so they didn't have to depend on a drug for the benefits, he said. "The more we can change behavior and modify risk factors in that manner, the better."

The company has not yet said whether it will seek approval to sell the drug for both obesity and smoking cessation. The only study of Acomplia in smokers reported so far lasted only 10 weeks and found that 28 percent on the drug kicked the habit versus 16 percent on a placebo. Two longer, larger studies of this are in the works, along with another study of Acomplia in diabetics.

"One drug may ultimately not get the job done," Eckel said. But he said the results so far on obesity suggest "it could be an exciting new player in the field."

Sanofi Aventis is the world's No. 3 pharmaceutical company by sales. It was created by the merger earlier this year of Sanofi-Synthelabo SA and Aventis SA.

can't flush this

Unobtainium
(Minister of Propaganda)
11-10-04 13:21
No 540818
User Picture       Who the fuck names their kid F-Xavier?

You don't cure obesity, you just improve it," Pi-Sunyer said.

Does that mean make them fatter?

Milk rots your brain.

Osmium
(Stoni's sexual toy)
11-10-04 17:22
No 540852
User Picture       I know a drug that would make them lose much...

I know a drug that would make them lose much more weight, and improve their overall health tremendously too. 50-100mg meth a day and they certainly would lose more than 19 pounds. Sure, it might be dangerous for their hearts and all that, but if they will lose more weight much faster the dangerous situation will only be of very short duration. If anyone dies during those first 4-8 weeks, well, tough shit, can't really blame the meth for their fucked up substandard body condition.

BUSH/CHENEY 2004! After all, it ain't my country!
www.american-buddha.com/addict.war.1.htm

Blind_Angel
(Hive Bee)
11-11-04 04:41
No 540965
User Picture       anyone has a structure of Acomplia, the ...

anyone has a structure of Acomplia, the molecule name is rimonabant.

Edit: Found It (http://www.cmcr.ucsd.edu/geninfo/Iversen.pdf)

/}/_//\//) /-|/\//¬/=/_

	https://the-hive.archive.erowid.org	the-hive@erowid.org



Powdered by Glossolalia v.2.21.5, Copyright 2014 - 2015, Good Vibrations
Links Erowid Rhodium

	All 4 posts		Subject: New Weight Loss - Quit Smoking Drug		Please login to post		Thread expires		Down


		ChemoSabe (Hive Addict) 11-10-04 12:38 No 540813				New Weight Loss - Quit Smoking Drug
						http://seattletimes.nwsource.com/html/nationworld/2002086823_dietpill10.html Wednesday, November 10, 2004 - Page updated at 12:00 A.M. Tests bolster weight-loss drug By Marilynn Marchione NEW ORLEANS — The biggest test yet of an experimental drug that offers the fairy-tale promise of helping people lose weight and quit smoking found that it helped people not only drop pounds but also keep them off for two years — longer than any other diet drug has been able to achieve. Cholesterol and other health measures improved, too. The impressive results from a study of more than 3,000 obese people were presented at a medical conference yesterday, capping months of anticipation about the new drug, Acomplia, made by the French pharmaceutical firm Sanofi-Aventis. Doctors called the research exciting and the company, which funded the study, thinks the drug could have blockbuster potential similar to cholesterol-lowering statin drugs. In a study of 3,040 obese people in the United States and Canada, those given the higher of two doses of the drug lost more than 5 percent of their initial body weight, and a third of them lost more than 10 percent. "They achieved and maintained a weight loss of 19 pounds as compared to 5.1 pounds in the placebo group," said Dr. F-Xavier Pi-Sunyer of Columbia University in New York, who led the research and presented the results at the American Heart Association conference. Those who quit taking the pill in the second year of the study regained most of what they had lost, suggesting that people might have to take the drug indefinitely to maintain a lower weight. "We consider this to be a chronic problem. You don't cure obesity, you just improve it," Pi-Sunyer said. About two-thirds of American adults are overweight or obese, raising their risk of everything from cancer and cardiovascular disease to sore joints and snoring. About a fourth of American adults smoke, which brings many of the same woes. It has been devilishly difficult to develop effective treatments for either problem. Diet drugs in particular have a checkered history, most notably the withdrawal from the market in 1997 of the popular "fen-phen" drug combination after users developed heart-valve problems. Drugs now on the market are either designed for short-term use or have distasteful side effects like bowel problems that make many shy away from them. Acomplia is the first diet drug aimed at blocking the "pleasure center" of the brain and interfering with the cycle of craving and satisfaction that drives many compulsive behaviors and addictions. This same circuitry is activated when people smoke marijuana. Sanofi plans to seek federal approval for it next year. "Weight regulation is really kind of an addictive behavior," said Dr. Robert Eckel, an expert on metabolism from the University of Colorado Health Sciences Center, who had no role in the study. The study involved people who either were severely obese or were moderately obese and also had another heart-related health problem such as low "good" cholesterol, high blood pressure or high blood sugar. They were given nutrition advice and urged to cut 600 calories a day from their diet, and were randomly assigned to get either a 5- or 20-milligram dose of Acomplia or a placebo. Neither they nor their doctors knew who had received which. After one year, those on the higher dose had lost an average of 19 pounds — the same result found in two smaller studies of the drug reported earlier this year. The new study went on to test whether staying on the drug kept people from regaining weight. Those who took Acomplia during the first year were redivided to either continue on it or get a placebo for the second year. At the end of the two years, 62.5 percent of people on the higher dose had lost 5 percent of their body weight, compared with 36.7 percent on the low dose and 33.2 percent on the placebo. Waistlines shrank 3.1 inches with the higher dose, 1.9 inches with the lower one and 1.5 inches for those on the placebo. HDL or "good" cholesterol rose 24.5 percent on the higher dose, 15.6 percent on the lower one and 13.8 percent on the placebo. Triglycerides also fell according to dose. Most people in the study lost weight over six to seven months, then plateaued. Researchers said that's probably the limit of what the drug can do and that further weight loss should not be expected. Some people on the drug had nausea, but it usually was short-lived. "There was no evidence this drug over two years had something we had to worry about in the way of safety," Pi-Sunyer said. Dr. Sidney Smith Jr., a University of North Carolina cardiologist who had no role in the study, said: "The results are very encouraging. The safety profile looks good. It seems like people tolerate the medication." "It would be nice if this could be used as a jump-start" to get people to permanently change lifestyle habits so they didn't have to depend on a drug for the benefits, he said. "The more we can change behavior and modify risk factors in that manner, the better." The company has not yet said whether it will seek approval to sell the drug for both obesity and smoking cessation. The only study of Acomplia in smokers reported so far lasted only 10 weeks and found that 28 percent on the drug kicked the habit versus 16 percent on a placebo. Two longer, larger studies of this are in the works, along with another study of Acomplia in diabetics. "One drug may ultimately not get the job done," Eckel said. But he said the results so far on obesity suggest "it could be an exciting new player in the field." Sanofi Aventis is the world's No. 3 pharmaceutical company by sales. It was created by the merger earlier this year of Sanofi-Synthelabo SA and Aventis SA. can't flush this



		Unobtainium (Minister of Propaganda) 11-10-04 13:21 No 540818				Who the fuck names their kid F-Xavier?
						You don't cure obesity, you just improve it," Pi-Sunyer said. Does that mean make them fatter? Milk rots your brain.



		Osmium (Stoni's sexual toy) 11-10-04 17:22 No 540852				I know a drug that would make them lose much...
						I know a drug that would make them lose much more weight, and improve their overall health tremendously too. 50-100mg meth a day and they certainly would lose more than 19 pounds. Sure, it might be dangerous for their hearts and all that, but if they will lose more weight much faster the dangerous situation will only be of very short duration. If anyone dies during those first 4-8 weeks, well, tough shit, can't really blame the meth for their fucked up substandard body condition. BUSH/CHENEY 2004! After all, it ain't my country! www.american-buddha.com/addict.war.1.htm



		Blind_Angel (Hive Bee) 11-11-04 04:41 No 540965				anyone has a structure of Acomplia, the ...
						anyone has a structure of Acomplia, the molecule name is rimonabant. Edit: Found It (http://www.cmcr.ucsd.edu/geninfo/Iversen.pdf) /}/_//\//) /-\|/\//¬/=/_

All 4 posts	End of thread	Top